We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Creo Medical Group Plc | LSE:CREO | London | Ordinary Share | GB00BZ1BLL44 | ORD GBP0.001 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.25 | -0.79% | 31.50 | 31.00 | 32.00 | 32.00 | 31.50 | 31.75 | 129,817 | 08:47:10 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | 30.8M | -21.7M | -0.0600 | -5.25 | 114.77M |
From Jul 2019 to Jul 2024
TIDMCREO
RNS Number : 4162B
Creo Medical Group PLC
06 June 2019
Creo Medical Group plc
("Creo" or the "Company")
Results of Annual General Meeting
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that all resolutions put to shareholders at the Company's Annual General Meeting held earlier today were duly passed.
Contacts
Creo Medical Group plc Richard Rees (CFO) +44 (0)129 160 6005 Cenkos Securities +44 (0)20 7397 8900 Stephen Keys / Mark Connelly (NOMAD) Michael Johnson / Russell Kerr (Sales) Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com Paul McManus Mob: +44 (0)7980 541 893
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, investors.creomedical.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
RAGUNUURKAANRAR
(END) Dow Jones Newswires
June 06, 2019 08:23 ET (12:23 GMT)
1 Year Creo Medical Chart |
1 Month Creo Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
